Matsumoto-shi
Matsumoto-shi
Matsumoto-shi, Japan20 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL | large B-cell lymphoma | Recruiting | Phase 3 | 2026-10-09 | NCT07215585 | |
| TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, proteostasis deficiencies | Recruiting | Phase 3 | 2026-10-08 | NCT07223203 | |
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Hypergammaglobulinemia, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, precancerous condition, smoldering plasma cell myeloma, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-10-07 | NCT07393282 | |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-02 | NCT06307652 | |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, proteinuria, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06291376 | |
| A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema | eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder | Recruiting | Phase 2 | 2026-10-01 | NCT06962839 | |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06935370 | |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-10-01 | NCT06424288 | |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, retinal disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-10-01 | NCT06321302 | |
| A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 3 | 2026-09-24 | NCT07624305 | |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Nutritional and Metabolic Diseases, amyloidosis, cardiomyopathy, cardiovascular disorder, heart disorder, metabolic disease, proteostasis deficiencies | Recruiting | Phase 3 | 2026-09-16 | NCT07052903 | |
| A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, chronic renal failure syndrome, kidney disorder, kidney failure, urinary system disorder | Recruiting | Phase 3 | 2026-09-09 | NCT07753993 | |
| Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, kidney disorder, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-19 | NCT06087835 | |
| An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia | Hyperkalemia, Nutritional and Metabolic Diseases, Water-Electrolyte Imbalance, metabolic disease | Recruiting | Phase 3 | 2026-08-13 | NCT03813407 | |
| Study of ALXN2220 Versus Placebo in Adults With ATTR-CM | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2026-08-10 | NCT06183931 | |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Active, not recruiting | Phase 3 | 2026-07-31 | NCT05138133 | |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Recruiting | Phase 3 | 2026-07-13 | NCT05712200 | |
| Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-06-25 | NCT04509700 | |
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2026-06-17 | NCT04512235 | |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | Cytopenia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Urogenital Diseases, anemia, atypical hemolytic-uremic syndrome, blood platelet disease, hematologic disorder, hemolytic anemia, hemolytic-uremic syndrome, kidney disorder, thrombocytopenia, thrombotic microangiopathy, uremia, urinary system disorder | Recruiting | Phase 4 | 2026-04-20 | NCT07308574 |